-transparent.png){kind=logo}
1 UK-37248 (dazoxiben), an orally active thromboxane synthetase inhibitor, was evaluated in a double-blind trial of patients with severe Raynaud's syndrome. 2 Twenty patients were enrolled in the study. Eleven of these patients received dazoxiben 400 mg day and nine received matching placebo capsules. Treatment was given for 6 weeks and the patients reviewed at 2 weekly intervals during the study. 3 Assessment of response was judged by clinical symptoms and hand temperature measurements. Haematological and haemostatic studies were also carried out. 4 Results show a significant clinical improvement in patients receiving dazoxiben for six weeks. Hand temperature measurements, and haematological and haemostatic blood tests remained unchanged, however, apart from the expected lowering in plasma thromboxane B2 levels. 5 The mechanism of action of the drug would appear not to be mediated through increased prostacyclin production and further studies are under way to determine how improvement has been obtained in these patients.
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
July 1984,
Clinical pharmacology and therapeutics,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
January 1984,
European journal of clinical pharmacology,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
September 1984,
The American journal of medicine,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
January 1983,
British journal of clinical pharmacology,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
June 1985,
Chest,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
September 1983,
Prostaglandins, leukotrienes, and medicine,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
February 1985,
European journal of clinical investigation,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
November 1993,
Critical care medicine,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
July 1988,
Prostaglandins, leukotrienes, and essential fatty acids,
J J Belch, and
J Cormie, and
P Newman, and
M McLaren, and
J Barbenel, and
H Capell, and
P Leiberman, and
C D Forbes, and
C R Prentice
February 1984,
Thrombosis and haemostasis,
